Ju Fu Tang Biotech Affirms Stable Capital Base in April 2026; Maintains Public-Float Compliance

Bulletin Express
05/05

Ju Fu Tang Biotech Holdings Co., Ltd (Ju Fu Tang Biotech) has filed its monthly return for the period ended 30 April 2026 with Hong Kong Exchanges and Clearing Ltd., indicating no change in share capital structure during the month.

Authorised and Issued Capital • Authorised share capital remained at 500.00 million ordinary shares with a par value of HKD 0.16 each, equivalent to HKD 80.00 million. • Issued share capital was unchanged at 301.86 million ordinary shares. No treasury shares were held or cancelled.

Public-Float Status The company confirmed that it continued to meet the minimum 25% public-float requirement stipulated under GEM Rule 17.37B as at 30 April 2026.

Share Option Schemes • Scheme granted 12 Jul 2021 (exercise price: HKD 0.315; expiry: 11 Jul 2026): 10.70 million options outstanding. • Scheme granted 18 Mar 2022 (exercise price: HKD 0.163; expiry: 17 Mar 2027): 9.14 million options outstanding. No options were exercised or cancelled during the month, leaving 19.84 million options outstanding and an equivalent number of shares available for potential future issuance.

Other Equity Instruments The issuer reported no warrants, convertible securities, other share-issuance agreements, or treasury-share movements in April.

Compliance Confirmation Corporate secretary Tam Mei Chu confirmed that all necessary authorisations and regulatory requirements were met for the period under review.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10